Tandem Diabetes Care (Nasdaq:TNDM) today announced the rollout of its latest automated insulin delivery system integration.

Tandem Diabetes has announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus ...

ABBOTT PARK, Ill., April 29, 2025 /PRNewswire/ -- Abbott (NYSE: ABT), the global leader in continuous glucose monitoring (CGM) biowearable technology 1, today announced that it has entered a ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the ...

The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

Abbott’s ABT diversified business portfolio is well-positioned to drive continued momentum in 2025. Foreign exchange remains a major headwind for Abbott. The stock currently carries a Zacks Rank #3 ...

Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the ...

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, ...

We recently published a list of Jim Cramer Talked About These 7 Stocks Recently. In this article, we are going to take a look at where Abbott Laboratories (NYSE:ABT) stands against other stocks that ...